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Introduction: With the progress made in treatments, the survival rate for patients with malignant lymphoma in the
last 30 years has significantly improved. However, the risk of experiencing a second primary malignancy or other
disease has increased significantly.
Case presentation: A 44-year-old Mongolian man with a large mass in his right lower abdomen was admitted to
our hospital 15 years previously. The mass was removed, and confirmed via pathological examination to be a
malignant B-cell lymphoma in the appendix and distal small bowel. Post-operative chemotherapy with standard
cyclophosphamide, hydroxydaunomycin, vincristine (OncovinW) and prednisolone regimen was given for six cycles.
No obvious recurrence was detected over the following 12 years. Subsequently, a mass in the right lung was found
on a regular X-ray follow-up; our patient did not report chills, fever or cough. Chest computed tomography and
positron emission tomography scans confirmed the mass. A primary lung carcinoma was considered to be the
most likely diagnosis. However, after an exploratory thoracotomy and right upper lobectomy was performed a
pathological examination of tissue samples demonstrated a lung cryptococcal granuloma, with positive staining for
periodic acid Schiff and periodic acid-silver metheramine.
Conclusions: Compared to the normal population, second primary malignancy (in particular leukaemia and lung
cancer) in patients with malignant lymphoma during their long-term survival has been seen occasionally. However,
other diagnoses should also be considered such as pulmonary cryptococcosis. Other than computed-tomography
-guided needle biopsy, surgery for some patients is a much more appropriate choice, which could also help attain
correct diagnosis and treatment.Introduction
With the progress made in treatments, in the last 30 years
the survival rate for patients with malignant lymphoma
has significantly improved. Use of the targeted drug rituxi-
mab in CD20(+) B-cell lymphoma has greatly increased
the efficiency of treatment and five-year survival rate.
However, compared to the normal population, the risk of
suffering a second primary malignancy, in particular
leukemia and lung cancer, has increased significantly in
patients with malignant lymphoma during their long-term
survival after treatment [1-3]. Usually, the first diagnosis
in these patients with a mass found during regular* Correspondence: xzhong9@gmail.com
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reproduction in any medium, provided the orfollow-up is a tumor. However, on occasion this could
be the wrong conclusion.Case presentation
A 44-year-old Mongolian man with a large mass in his
right lower abdomen presented to our hospital 15 years
ago. After completion of relevant physical and laboratory
examinations, abdominal laparotomy was performed
under general anesthesia, and the mass was removed.
Pathological examination and immunohistochemical
staining of tissue samples showed a malignant B-cell
lymphoma in the appendix and small bowel. Post-d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chest computed tomography scan showing a mass with signs of lobulation and burr, sized 2.4×2.0cm, in the dorsal section
of the right lung.
Figure 2 An 18F-fluorodeoxyglucose (FDG) positron electron
tomography (PET) scan showing lesions with obviously
increased standardized uptake values (SUVs) in the lower lobe
and hilum of the right lung.
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mide, hydroxydaunomycin, vincristine (OncovinW) and
prednisolone (CHOP) regimen was given for six cycles.
No obvious recurrence was detected during regular
follow-up appointments over the following 12 years.
Then, three years ago, a mass in the right lung was
detected during a regular X-ray follow-up. Our patient
reported no chills, fever or cough. The results of a phys-
ical examination were unremarkable. A chest computed
tomography (CT) scan showed a mass with lobulation
and burr in the dorsal section of the right lung, sized
2.4×2.0cm (Figure 1). An 18 F-fluorodeoxyglucose
(FDG) positron emission tomography (PET) scan
showed lesions with obviously increased standardized
uptake values (SUVs) in the lower lobe and hilum of the
right lung. The maximum SUVs of the lesions on the
initial scans were 17.8 and 4.1, respectively, while the
maximum values on later scans were elevated to 22.0
and 4.3, respectively (Figure 2). A bone scintigraphy
scan, brain magnetic resonance (MRI) and ultrasound
examination of the upper abdomen all showed no abnor-
mal signs. The results of an anti-human immunodefi-
ciency virus (HIV) antibody test were negative. A
tuberculin test was also negative.
A multidisciplinary discussion of our patient’s case was
carried out. Primary lung carcinoma was considered to
be the most likely diagnosis. Our patient refused to
undergo a CT-guided needle biopsy and asked for ex-
ploratory thoracotomy instead. Considering our patient’s
wishes, a right exploratory thoracotomy and right upper
lobectomy was performed under general anesthesia. Patho-
logical examination of samples showed lung cryptococcal
granuloma, with positive staining with periodic acid Schiff
(PAS) and periodic acid-silver metheramine (PASM). No
acid-fast bacilli were found. All the lymph nodes including
six of the bronchial lymph nodes, two of group 2, two of
group 3, five of group 4, five of group 7 and one of group 8
showed chronic inflammation (Figure 3). Our patient was
treated with fluconazole tablets post-operatively (0.2g once
Figure 3 A pathological examination demonstrated lung
cryptococcal granuloma (×400).
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Our patient was followed up by monthly review; no recur-
rence had been found to date, more than 18 months after
he underwent chest surgery.Conclusions
Diagnosis of pulmonary cryptococcosis usually depends
on the etiology of infected tissue cultures or pathology
findings. Surgery, percutaneous needle biopsy, bronchos-
copy brushing or biopsy, bronchoalveolar lavage fluid cul-
ture, smear or culture of cerebrospinal fluid and lymph
node biopsy are all effective methods for diagnosis. Com-
bined with the results of PET and lung CT scans, our
patient was suspected to have a second tumor: primary
lung cancer. However, pathological examination verified
the primary pulmonary cryptococcosis, caused by infec-
tion of Cryptococcus neoformans. Our patient denied an
exposure history of bird secretions, dust and pollen. Previ-
ous studies have reported that T-cell-mediated immune
dysfunction often occurs in patients with cancer after
chemotherapy, who are susceptible to pulmonary crypto-
coccosis [4,5]. We believe that surgery for such patients is
a more appropriate choice, at least in some cases, which
could also help attain correct diagnosis and treatment.Consent
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